EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY Financials Egyptian International Pharmaceutical Industries Company
Equities
PHAR
EGS38081C013
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.97 EGP | +2.77% |
|
-13.97% | -1.45% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,592 | 4,309 | 4,155 | 3,621 | 5,430 | 5,351 | - | - |
| Enterprise Value (EV) 1 | 6,592 | 5,356 | 5,592 | 5,985 | 9,634 | 11,881 | 11,962 | 11,910 |
| P/E ratio | 9.83 x | - | - | - | - | - | - | - |
| Yield | - | 6.79% | 3.58% | - | - | 6.95% | 8.34% | - |
| Capitalization / Revenue | 1.93 x | 1.48 x | 1.21 x | 0.92 x | 1.04 x | 0.75 x | 0.64 x | 0.55 x |
| EV / Revenue | 1.93 x | 1.84 x | 1.63 x | 1.51 x | 1.84 x | 1.67 x | 1.42 x | 1.22 x |
| EV / EBITDA | 7.53 x | 6.8 x | 5.57 x | 6.85 x | 6.56 x | 5.95 x | 5.02 x | 4.27 x |
| EV / FCF | 63.9 x | -138 x | -105 x | -6.35 x | -4.38 x | 36 x | 11.1 x | 9.83 x |
| FCF Yield | 1.57% | -0.72% | -0.95% | -15.8% | -22.8% | 2.78% | 9.05% | 10.2% |
| Price to Book | 2.23 x | 1.49 x | 1.46 x | 1.12 x | 1.28 x | 1.24 x | 1.1 x | - |
| Nbr of stocks (in thousands) | 99,171 | 99,171 | 99,171 | 99,171 | 148,756 | 148,756 | - | - |
| Reference price 2 | 66.47 | 43.45 | 41.90 | 36.51 | 36.50 | 35.97 | 35.97 | 35.97 |
| Announcement Date | 2/27/20 | 2/25/21 | 2/23/22 | 3/1/23 | 3/1/24 | - | - | - |
1EGP in Million2EGP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,411 | 2,910 | 3,437 | 3,955 | 5,232 | 7,103 | 8,412 | 9,780 |
| EBITDA 1 | 875.7 | 787.2 | 1,004 | 874.2 | 1,469 | 1,996 | 2,385 | 2,786 |
| EBIT 1 | 728.9 | 647.6 | 894.8 | 774.9 | 1,364 | 1,813 | 2,167 | - |
| Operating Margin | 21.37% | 22.26% | 26.04% | 19.59% | 26.08% | 25.52% | 25.76% | - |
| Earnings before Tax (EBT) 1 | 840.6 | 595.3 | 688.7 | 804.7 | 1,083 | 1,129 | 1,402 | - |
| Net income 1 | 670.6 | 486.5 | 522.8 | 643.8 | 823.3 | 874 | 1,085 | - |
| Net margin | 19.66% | 16.72% | 15.21% | 16.28% | 15.74% | 12.3% | 12.9% | - |
| EPS | 6.762 | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 103.2 | -38.7 | -53.27 | -943 | -2,200 | 330 | 1,082 | 1,211 |
| FCF margin | 3.03% | -1.33% | -1.55% | -23.84% | -42.05% | 4.65% | 12.86% | 12.38% |
| FCF Conversion (EBITDA) | 11.78% | - | - | - | - | 16.53% | 45.37% | 43.47% |
| FCF Conversion (Net income) | 15.39% | - | - | - | - | 37.76% | 99.72% | - |
| Dividend per Share 2 | - | 2.950 | 1.500 | - | - | 2.500 | 3.000 | - |
| Announcement Date | 2/27/20 | 2/25/21 | 2/23/22 | 3/1/23 | 3/1/24 | - | - | - |
1EGP in Million2EGP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2023 Q4 |
|---|---|---|
| Net sales 1 | 899.3 | 1,551 |
| EBITDA 1 | - | 377.6 |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income | - | - |
| Net margin | - | - |
| EPS | - | - |
| Dividend per Share | - | - |
| Announcement Date | 11/7/21 | 3/1/24 |
1EGP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1,047 | 1,437 | 2,364 | 4,204 | 6,530 | 6,611 | 6,559 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 1.33 x | 1.431 x | 2.704 x | 2.861 x | 3.272 x | 2.772 x | 2.354 x |
| Free Cash Flow 1 | 103 | -38.7 | -53.3 | -943 | -2,200 | 330 | 1,082 | 1,211 |
| ROE (net income / shareholders' equity) | 23.4% | 16.8% | 18% | 20% | 22% | 19.1% | 21.3% | 25% |
| ROA (Net income/ Total Assets) | 16.2% | 10.3% | 10.1% | - | - | - | - | - |
| Assets 1 | 4,143 | 4,724 | 5,153 | - | - | - | - | - |
| Book Value Per Share 2 | 29.70 | 29.10 | 28.70 | 32.70 | 28.60 | 29.10 | 32.60 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 177 | 204 | 437 | 562 | 2,290 | 800 | 271 | 315 |
| Capex / Sales | 5.19% | 7% | 12.72% | 14.21% | 43.78% | 11.26% | 3.22% | 3.22% |
| Announcement Date | 2/27/20 | 2/25/21 | 2/23/22 | 3/1/23 | 3/1/24 | - | - | - |
1EGP in Million2EGP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
35.97
EGP
Average target price
75.3
EGP
Spread / Average Target
+109.34%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.45% | 112M | |
| +19.98% | 43.67B | |
| +20.67% | 22.51B | |
| +14.56% | 14.6B | |
| +14.32% | 13.74B | |
| +44.72% | 11.91B | |
| -8.37% | 7.04B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.39% | 5.42B |
- Stock Market
- Equities
- PHAR Stock
- Financials Egyptian International Pharmaceutical Industries Company
